FLT3 and acute myeloid leukemia: Collectively, these trials provided important data regarding the efficacy of FLT3 inhibitors for AML treatment, and their application, particularly in combination with traditional chemotherapeutic agents as well as novel agents, would represent an important shift in the outcome of pediatric AML patients.